S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:VIRX

Viracta Therapeutics (VIRX) Stock Price, News & Analysis

$1.08
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$1.05
$1.10
50-Day Range
$0.48
$1.13
52-Week Range
$0.43
$2.38
Volume
32,881 shs
Average Volume
116,641 shs
Market Capitalization
$42.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Viracta Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
363.0% Upside
$5.00 Price Target
Short Interest
Healthy
2.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Viracta Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$2,486 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.28) to ($1.27) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.93 out of 5 stars

Medical Sector

626th out of 939 stocks

Pharmaceutical Preparations Industry

289th out of 427 stocks

VIRX stock logo

About Viracta Therapeutics Stock (NASDAQ:VIRX)

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor; and VRx-510, a preclinical-stage PDK-1 inhibitor. The company was formerly known as Sunesis Pharmaceuticals, Inc. and changed its name to Viracta Therapeutics, Inc. in February 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.

VIRX Stock Price History

VIRX Stock News Headlines

Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
VIRX Mar 2024 2.500 call
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
Viracta Therapeutics Inc VIRX
Viracta Therapeutics: Q3 Earnings Insights
Viracta Therapeutics to Host R&D Day on October 4, 2023
Expert Ratings for Viracta Therapeutics
RBC Capital Sticks to Their Buy Rating for Viracta Therapeutics (VIRX)
Viracta Therapeutics (VIRX) Receives a Buy from H.C. Wainwright
See More Headlines
Receive VIRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/27/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VIRX
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+363.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-51,060,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.33 per share

Miscellaneous

Free Float
36,358,000
Market Cap
$42.41 million
Optionable
Optionable
Beta
0.95
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Mark Andrew Rothera (Age 61)
    CEO, President & Director
    Comp: $365.03k
  • Mr. Daniel R. Chevallard CPAMr. Daniel R. Chevallard CPA (Age 44)
    CFO, COO, Treasurer & Secretary
    Comp: $647.91k
  • Dr. Susan Perrine M.D.
    Scientific Founder and Consultant
  • Dr. Ronald J. Berenson M.D. (Age 72)
    Co-Founder and Consultant
  • Mr. George Hillman
    Co-Founder
  • Dr. Thalia Papayannopoulou M.D.
    Co-Founder
  • Dr. Robert M. Williams Ph.D. (Age 69)
    Co-Founder
  • Dr. Douglas V. Faller M.D.
    Ph.D., Scientific Founder & Chairman of Scientific Advisory Board
  • Dr. Ayman El-Guindy
    Chief Scientific Officer
  • Mr. Stewart M. Brown
    Senior VP of Legal Affairs & General Counsel

VIRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Viracta Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viracta Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VIRX shares.
View VIRX analyst ratings
or view top-rated stocks.

What is Viracta Therapeutics' stock price target for 2024?

3 Wall Street research analysts have issued 1-year target prices for Viracta Therapeutics' stock. Their VIRX share price targets range from $4.00 to $6.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 363.0% from the stock's current price.
View analysts price targets for VIRX
or view top-rated stocks among Wall Street analysts.

How have VIRX shares performed in 2024?

Viracta Therapeutics' stock was trading at $0.57 at the beginning of the year. Since then, VIRX stock has increased by 89.5% and is now trading at $1.08.
View the best growth stocks for 2024 here
.

When is Viracta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our VIRX earnings forecast
.

How were Viracta Therapeutics' earnings last quarter?

Viracta Therapeutics, Inc. (NASDAQ:VIRX) announced its earnings results on Thursday, March, 7th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.05.

Who are Viracta Therapeutics' major shareholders?

Viracta Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.96%), Citadel Advisors LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Daniel R Chevallard, Ivor Royston, Lisa Rojkjaer and Mark Rothera.
View institutional ownership trends
.

How do I buy shares of Viracta Therapeutics?

Shares of VIRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VIRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners